MC 207252
Latest Information Update: 27 Dec 2000
At a glance
- Originator Essential Therapeutics [CEASED]
- Developer Daiichi Pharmaceutical; Essential Therapeutics [CEASED]
- Class Antibacterials
- Mechanism of Action P-glycoprotein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 27 Dec 2000 Discontinued-Preclinical for Bacterial infections in Japan (Unknown route)
- 27 Dec 2000 Discontinued-Preclinical for Bacterial infections in USA (Unknown route)
- 04 Aug 1998 No-Development-Reported for Bacterial infections in Japan (Unknown route)